Summary of Twist Bioscience Conference Call Company Overview - **Company**: Twist Bioscience (NasdaqGS:TWST) - **Event**: 2026 Conference on March 11, 2026 - **Speakers**: CEO Emily Leproust, CFO Adam Laponis Key Industry Insights - **Industry**: Life Sciences, specifically focusing on Next-Generation Sequencing (NGS) and AI-driven drug discovery - **Market Growth**: Twist Bioscience reported a **20% growth** for fiscal year 2025 and **17% growth** in the last quarter, outperforming peers in the DNA, oligos, probes, and kits sector which faced challenges last year [3][5][17] Core Business Strategies - **Revenue Growth Drivers**: - Combination of gaining market share, new product introductions, and expanding accounts [3][5] - Significant focus on new product introduction (NPI) with a market size increase from **$2 billion in 2020 to $7 billion** in 2025 [5] - Emphasis on commercial excellence to outperform competitors [6] - **AI Drug Discovery**: - Rapid growth in AI-driven drug discovery services, with a notable increase in sales from zero to a fast-growing product line [8][10] - Ability to handle thousands of sequences with a delivery time of **15-20 days**, which is considered best in class [15] Financial Performance - **Gross Margin Expansion**: - Achieved a **20-point increase** in gross margin from the low 30s to over **50%** over three years, with **75%-80%** of revenue growth contributing to gross margin [17][18] - **Operating Expenses**: - Maintained discipline in managing operating expenses while investing in growth, with a focus on achieving adjusted EBITDA breakeven by Q4 [18] Product Differentiation - **Protein Expression Services**: - Twist's differentiation lies in its ability to express thousands of proteins quickly, leveraging extreme automation and a robust software layer [21][24] - Capacity to produce **3 million genes per year**, with protein production timelines of **10 days for HEK** and **13 days for CHO** [24] - **Bispecific Antibodies**: - Recently licensed B-Body technology from Invenra to enhance bispecific antibody production, aiming to be the first to provide high-throughput bispecifics [66] Market Positioning - **Market Size and Competition**: - No specific market size provided, but the company is quantifying it and plans to share validated figures in the future [51] - Observed a mix of early and late adopters of AI in the top 20 pharma companies, with a focus on capturing net new dollars from AI drug discovery startups [52][53] Future Outlook - **Growth Strategy**: - Plans to continue expanding product offerings and enhancing service capabilities, particularly in therapeutics and AI [70] - Shift towards fee-for-service contracts to accelerate revenue generation, especially in bispecifics [75] - **Upcoming Events**: - An Investor Day is scheduled for May, with anticipation of significant announcements [120] Additional Considerations - **Customer Relationships**: - Strong customer retention noted, with inherent ordering patterns being inconsistent but manageable [111] - **MRD Product Development**: - Transitioning to MRD Express to provide probes in **1 day**, enhancing competitive positioning [118] This summary encapsulates the key points discussed during the Twist Bioscience conference call, highlighting the company's growth strategies, financial performance, product differentiation, and future outlook in the life sciences industry.

Group 1 - The company has experienced significant growth in its DNA Synthesis and Protein Solutions segments, with a year-over-year increase of 27% in Q1 [2] - The traditional drug discovery process involves in vivo/in vitro methods, where DNA is extracted from inoculated mice to screen for novel antibodies [3] - The company utilizes a large library of over 10 billion antibodies, employing phage display techniques to identify and characterize 10 to 100 antibodies for customer use [3] Group 2 - The resegmentation into SynBio and Protein Solutions is a key focus area for the company, indicating a strategic shift to capitalize on emerging trends in the industry [1] - The company is positioned as a leader in AI applications within its sector, although it does not utilize a specific AI plug-in like Claude [1]

Summary of Twist Bioscience FY Conference Call (March 10, 2026) Company Overview - **Company**: Twist Bioscience (NasdaqGS:TWST) - **Industry**: Life Science Tools and Diagnostics Key Points Financial Performance - DNA synthesis and protein solutions grew by **27% year-over-year** in Q1 [2] - Therapeutic drug discovery revenue was approximately **$111 million**, growing more than **25%** [3] - Data characterization grew by more than **200%** last year [36] - The company has a capacity for **3 million genes per year**, with **271,000 genes** shipped last quarter [34] AI and Drug Discovery - Traditional drug discovery methods are being replaced by AI, which allows for the generation of thousands of antibody sequences quickly [3][5] - AI reduces the time to identify a hit from **6 weeks** (in vivo/in vitro) to **2 weeks** [5] - Twist aims to provide a full menu of services, catering to both traditional and AI-driven drug discovery companies [7][8] Bispecific Antibodies - The company has partnered with Invenra to enhance its capabilities in bispecific antibody production, which is traditionally challenging due to the complexity of the process [16] - Invenra's platform allows for high-throughput expression and purification of bispecific antibodies, making it easier to integrate AI into the development process [17][22] NGS (Next-Generation Sequencing) Business - The NGS business is expected to grow by **20%** by Q4, with significant momentum in liquid biopsy and MRD (Minimal Residual Disease) diagnostics [44] - The introduction of TrueAmp for library preparation is aimed at expanding into new markets, including academia [55] Market Dynamics - The company is optimistic about the growth of the SynBio market and believes that the transition from exome to whole genome sequencing will benefit their business [48] - Twist is positioned to compete effectively against traditional methods by offering faster turnaround times and better accuracy [72] Margins and Profitability - Gross margins have improved to over **55%**, with expectations for continued growth as revenue increases [75] - The company targets **75%-80%** of revenue growth to contribute to gross margin, indicating strong operational leverage [76] Customer Engagement and Market Penetration - There is a focus on understanding customer needs and responding with tailored solutions, as seen with the development of MRD Express based on customer feedback [68][70] - The company is experiencing increased interest from customers who previously chose competitors, indicating a shift in market sentiment [74] Future Outlook - The company is committed to maintaining high-quality service while expanding capacity to meet growing demand [32] - There is a cautious optimism about future revenue growth and margin expansion, with a focus on strategic investments in capabilities [77] Additional Insights - The company emphasizes a customer-centric approach, aiming to meet clients where they are in their drug discovery processes [8] - The integration of AI into their workflows is seen as a key differentiator in the competitive landscape [4][5]

Summary of Twist Bioscience FY Conference Call Company Overview - **Company**: Twist Bioscience (NasdaqGS:TWST) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 03, 2026 Key Points Financial Performance and Strategy - Twist is on track to achieve adjusted EBITDA breakeven by Q4 of fiscal year 2026, with a focus on maximizing revenue growth while maintaining cost discipline [4][5] - The company has ramped revenue significantly, with 75%-80% of new revenue contributing to gross margin, improving from low 30s to over 50% [5][6] - The Total Addressable Market (TAM) has expanded from $2 billion in 2020 to $7 billion currently, with expectations to reach $12 billion by 2030 [7] AI and Therapeutics Segment - The therapeutic segment generated $111 million in revenue last year, growing over 25%, driven by AI capabilities in drug discovery [11] - Twist has developed automated high-throughput capabilities to meet the increasing demand for data from customers, particularly in the AI space [13][14] - The company emphasizes the importance of speed, throughput, and affordability in meeting customer needs, with a turnaround time of 17 days for data delivery, significantly faster than competitors [19][20] Market Dynamics and Competitive Advantage - Twist's competitive edge lies in its ability to provide high-quality data quickly and at scale, leveraging extreme automation and digital tracking [21][22] - The company is positioned to capitalize on the growing investment in AI by pharma and biotech companies, which are increasingly seeking efficient solutions for drug discovery [12][17] MRD (Minimal Residual Disease) Market - Twist is focusing on high sensitivity in cancer diagnostics, particularly in the MRD space, which saw over 200% growth last year [34] - The company offers a tumor-informed tool set with a significant number of probes at competitive pricing, enhancing sensitivity for MRD testing [33] - Expected revenue contribution from MRD is projected to be 1 to 2 percentage points of overall growth, with a ramp-up anticipated in the latter half of the year [36] Future Outlook - Twist aims to dominate the market, aspiring to achieve 100% market share in its segments [48] - The company is committed to continuous product innovation and commercialization efforts to expand its market presence [49] - The long-term growth strategy includes leveraging AI advancements and expanding the product portfolio to capture a larger share of the evolving market [48] Licensing and Partnerships - Twist announced a licensing deal with Invenra for bispecific technology, which is expected to facilitate AI-driven drug discovery [28][29] - The partnership aims to enhance Twist's capabilities in producing bispecific antibodies, which are challenging to manufacture at scale [29] Additional Insights - The company is focused on customer experience and repeat business, emphasizing the importance of delighting customers to foster loyalty and growth [24][25] - Twist is aware of the challenges in traditional drug discovery and aims to meet customers where they are, providing tailored solutions [26] This summary encapsulates the key insights from the Twist Bioscience conference call, highlighting the company's strategic direction, market opportunities, and competitive advantages in the biotechnology sector.

Core Viewpoint - Twist Biosciences is discussing a license agreement for its B-Body bispecific technology platform during a conference call, indicating a strategic move to enhance its product offerings and market position [1][2]. Group 1: Company Overview - The conference call features key executives including Dr. Emily Leproust (CEO), Adam Laponis (CFO), Dr. Patrick Finn (President and COO), and Dr. Colby Souders (CSO), highlighting the leadership team's involvement in the company's strategic initiatives [3]. - The press release regarding the license agreement was made available on the company's website, demonstrating transparency and communication with stakeholders [2]. Group 2: Conference Call Details - The call is being recorded and will be archived in the Investors section of the company's website for two weeks, ensuring that interested parties can access the information later [3]. - Participants are encouraged to limit their questions to one during the Q&A session, promoting an orderly discussion [3].

Twist Licenses Bispecific Platform February 2026 Legal Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the ability to utilize the B- Body platform to expand service offerings and meet future demand for bisp ...

Industry Overview - The biotech industry had a strong performance in 2025, outperforming NVIDIA, with continued enthusiasm into 2026 [5] - There are concerns regarding the FDA's regulatory environment, described as chaotic, which may impact drug approvals [5][9] FDA Regulatory Environment - Richard Pasdur, a former senior FDA executive, expressed concerns about the breach of the firewall between political appointees and drug reviewers, indicating potential risks for the pharma industry [7] - The FDA's current commissioner, Marty Makary, aims to speed up drug approvals, but there are conflicting signals regarding the actual operating reality [9] Company Earnings Predictions Eli Lilly (Ticker: LLY) - Expected earnings per share range from $6.99 to $7.86, with a consensus estimate of $7.48 and revenue of $17.85 billion, indicating over 30% year-over-year earnings growth [15] - Analysts predict a likely earnings beat due to a history of exceeding expectations [15][16] Novo Nordisk (Ticker: NVO) - Earnings per share expectations are between $0.89 and $0.90, with revenue projected at $11.96 billion, showing a flat to slightly down trend [17] - Analysts express a higher possibility of a miss compared to Eli Lilly, citing recent struggles and a new CEO's uncertain direction [17][19] Twist Bioscience (Ticker: TWST) - Reported revenue of $104 million for Q1 2026, consistent with preliminary results, though still unprofitable [20] - The company has shown consistent revenue growth despite industry challenges, reducing cash burn and moving towards profitability [20]

Company Overview - Twist Bioscience's stock has experienced a significant rebound in recent months, attributed to increasing optimism surrounding AI-enabled drug discovery and the adoption of minimal residual disease (MRD) testing [1] - The Biopharma segment of Twist is reaccelerating, driven by customers engaged in AI-enabled drug discovery and next-generation sequencing (NGS) [1] Investment Strategy - Narweena, an asset management firm led by Richard Durant, focuses on identifying market dislocations caused by a poor understanding of long-term business prospects, aiming for excess risk-adjusted returns [1] - The research process at Narweena emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and a long-term investment horizon [1] - The firm targets smaller cap stocks and markets where competitive advantages are not immediately apparent, driven by the belief that an aging population and low growth will create new investment opportunities [1] Market Dynamics - Many industries are expected to face stagnation or secular decline, which may paradoxically enhance business performance due to reduced competition [1] - Conversely, some businesses may encounter rising costs and diseconomies of scale, impacting their performance negatively [1] - The economy is increasingly characterized by asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1] Leadership Background - Richard Durant holds undergraduate degrees in engineering and finance from the University of Adelaide and an MBA from Nanyang Technological University, where he was on the Dean's Honors List [1] - He has successfully passed the CFA exams, indicating a strong foundation in financial analysis [1]

Company Overview - Twist Bioscience's stock has experienced a significant rebound in recent months, attributed to increasing optimism surrounding AI-enabled drug discovery and the adoption of minimal residual disease (MRD) testing [1] - The Biopharma segment of Twist is reaccelerating, driven by customers engaged in AI-enabled drug discovery and next-generation sequencing (NGS) [1] Investment Strategy - Narweena, an asset management firm led by Richard Durant, focuses on identifying market dislocations caused by a poor understanding of long-term business prospects, aiming for excess risk-adjusted returns [1] - The research process at Narweena emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and a long-term investment horizon [1] - The firm targets smaller cap stocks and markets where competitive advantages are not immediately apparent, driven by the belief that an aging population and low growth will create new investment opportunities [1] Market Dynamics - Many industries are expected to face stagnation or secular decline, which may paradoxically enhance business performance due to reduced competition [1] - Conversely, some businesses may encounter rising costs and diseconomies of scale, impacting their performance negatively [1] - The economy is increasingly characterized by asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1]

Corporate Governance - Twist Bioscience held its 2026 annual meeting of stockholders via an online webcast, focusing on electing directors, conducting a non-binding advisory vote on executive compensation, and ratifying the independent auditor for fiscal 2026 [2] - All three director nominees—Keith Crandell, Jan Johannessen, and Trynka Shineman Blake—were elected, and the advisory vote on executive compensation was approved [6] Meeting Logistics - The meeting was chaired by Lead Independent Director Robert Chess, with attendance from various directors and company officers, including CEO Emily Leproust [3][4] - The board set December 26, 2025, as the record date for determining stockholders entitled to vote, with proxies received for 56,260,506 shares, representing approximately 91.81% of total votes [5][6] Auditor Ratification - Stockholders ratified Ernst & Young LLP as the auditor for fiscal 2026, with a full vote tally to be filed on Form 8-K within four business days [6]